Accession Number:



Early Detection of NSCLC Using Stromal Markers in Peripheral Blood

Descriptive Note:

Technical Report,01 Sep 2014,31 Aug 2017

Corporate Author:

Weill Cornell Medical College of Cornell University New York United States

Personal Author(s):

Report Date:


Pagination or Media Count:



A recent screening trial showed that the use of low dose computed tomography LDCT resulted in a 20 reduction in lung cancermortality, however there was a 96 false positive rate associated with LDCT. Thus, there is an immediate clinical need to develop diagnostic biomarker that would select patients with CT detected nodules for further testing. The ease with which blood can be sampled makes it a logical choice in which to discover diagnostic biomarkers, however the clinical utility of tumor derived proteins, miRNA or circulating tumor cells as blood-based biomarkers has been limited. In this proposal, instead of tumor-derived biomarkers, we will focus on host response to tumor growth. It has been well documented that tumor growth systemically stimulates and mobilizes BM-derived hematopoietic cells to the tumor bed to establish a permissive microenvironment. Preliminary studies in our lab have shown that in lung cancer patients, the circulating myeloid cells are transcriptionally altered and the alteration is tumor dependent. The specific transcriptomic signature of circulating myeloid cells may provide us unique resources for lung cancer biomarker discovery. Therefore, we hypothesized that the circulating BM-derived myeloid cells carry specific transcriptomic signature, which may be useful for early lung cancer diagnosis. The specific aims are Aim 1. To identify a NSCLC-dependent transcriptomic signature in circulating myeloid cells. Aim 2. To validate the diagnostic value of the specific gene signatures of circulating myeloid cells in NSCLC patients with lung nodules.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: